Lun - Ven 8:00 - 17:00

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

Education environnementale
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

Ecotourisme
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

Développement Communautaire
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

ODDB ONG

FDA approves expanded use of flibanserin for hypoactive sexual desire disorder in women

Other > flibanserin


^ FDA seeks more tests on a female Viagra, by Matthew Perrone, The Detroit Free Press, page 2A Wednesday, 12 February 2014 "FDA: Female sex drive drug needs more research - CNN.com".

Results In As Little As 4 Weeks

[17][18] Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown (although it might be caused by the competition with endogenous serotonin), flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. [4][19] Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. [17] Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor. [15] As such, flibanserin has been described as a norepinephrine–dopamine disinhibitor (NDDI). The proposed mechanism of action refers to the Kinsey dual control model of sexual response.

Acquisition by Valeant Pharmaceuticals

[21] Various neurotransmitters, sex steroids, and other hormones have important excitatory or inhibitory effects on the sexual response. Among neurotransmitters, excitatory activity is driven by dopamine and norepinephrine, while inhibitory activity is driven by serotonin. The balance between these systems is of significance for a normal sexual response. By modulating serotonin and dopamine activity in certain parts of the brain, flibanserin may improve the balance between these neurotransmitter systems in the regulation of sexual response. Flibanserin was originally developed as an antidepressant,[24][15] but was found to have pro-sexual effects and was later repurposed for the treatment of hypoactive sexual desire disorder.

InChI key

In June 2010, a federal advisory panel to the US Food and Drug Administration (FDA) unanimously voted against recommending approval of flibanserin, citing an inadequate risk-benefit ratio. The committee acknowledged the validity of hypoactive sexual desire as a diagnosis, but expressed concern with the drug's side effects and insufficient evidence for efficacy, especially the drug's failure to show a statistically significant effect on the co-primary endpoint of sexual desire. [25] Ahead of the votes, Boehringer Ingelheim had mounted a publicity campaign to promote the controversial disorder of "hypoactive sexual desire". [26] In 2010, the FDA issued a Complete Response Letter, stating that the new drug application could not be approved in its current form. The letter cited several concerns, including the failure to demonstrate a statistical effect on the co-primary endpoint of sexual desire and overly restrictive entry criteria for the two phase III trials. Archived from the original on 1 August 2017. "Advisers To FDA Recommend Agency Approve Drug To Boost Female Libido".

Region Estimated Cost per Month Generic Version Available
USA $400 No
EU €350 No
Australia AUD 550 No
India Approx. $50 (generic) Yes

Archived from the original on 4 June 2015. ^ "Critics: Women's Sex Pill Approval Vote Driven By PR, Not Science".

Country Approval Status Year
United States Approved 2015
Canada Approved 2016
European Union Pending/Under review N/A
Australia Not approved N/A

Archived from the original on 4 March 2021.

Product Dosage Quantity + Bonus Price
Cialis Generic20mg30 + 4 Pills68.05€ 64.81€
Kamagra100mg84 + 6 Pills264.44€ 251.85€
Kamagra100mg20 Pills86.09€ 81.99€
Levitra Original20mg34 + 2 Pills188.51€ 179.53€
Priligy Generic Dapoxetine60mg60 + 8 Pills183.06€ 174.34€
Kamagra Effervescent Tablets100 mg84 + 7 Pills202.91€ 193.25€
Cialis Generic2.5mg10 Pills28.51€ 27.15€
Viagra Soft Tabs100mg30 + 4 Pills83.06€ 79.10€
Levitra Generic40mg360 + 10 Pills704.99€ 671.42€
Cialis Professional40mg30 Pills148.94€ 141.85€
Super Kamagra160 mg32 + 4 Pills218.25€ 207.86€
Cialis Generic40mg360 + 10 Pills477.87€ 455.11€
Viagra Oral Jelly100mg10 Sachets46.36€ 44.15€

"First drug to improve sexual desire in women approved in the United States".

  • The pharmacology of flibanserin demonstrates a complex serotonin-dopamine interplay.
  • The medication is not a substitute for addressing relationship or psychological factors.
  • It is essential to evaluate contraindications before prescribing flibanserin.
  • The drug's societal impact includes increased awareness of female sexual health.
  • Use during pregnancy is contraindicated due to unknown risks.
  • Flibanserin requires healthcare provider supervision due to its safety profile.
  • Its effectiveness varies, necessitating personalized treatment approaches.
  • Ongoing studies seek to expand understanding of its benefits and risks.
  • The medication represents a milestone in female sexual medicine advancements.

Archived from the original on 13 February 2021. Archived from the original on 7 April 2021.

Further reading

The FDA recommended performing a new phase III trial with less restrictive entry criteria. [27] In October 2010, Boehringer announced that it would discontinue its development of flibanserin in light of the FDA's decision. Sprout responded to the FDA's cited deficiencies and refiled the new drug application in 2013. The submission included data from a new phase III trial and several phase I drug-drug interaction studies. [27][29] The FDA again refused the application, citing an uncertain risk/benefit ratio.

Generic Name

In December 2013, a Formal Dispute Resolution was filed,[30] which contained the requirements of the FDA for further studies. These include two studies in healthy subjects to determine if flibanserin impairs their ability to drive, and to determine if it interferes with other biochemical pathways. The Agency agreed to call a new Advisory Committee meeting to consider whether the risk-benefit ratio of flibanserin was favorable after this additional data was obtained. In June 2015, the US FDA Advisory Committee, which includes the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM), recommended approval of the drug by 18–6, with the proviso that measures be taken to inform women of the drug's side effects. [33][34] On 18 August 2015, the FDA approved Addyi (flibanserin) for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties.

Pediatric Precautions

The approval specified that flibanserin should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects. As of August 2015, Sprout Pharmaceuticals had not yet made an application to bayer vardenafil the European Medicines Agency for a marketing authorization. Even the Score, a coalition of women's groups brought together by a Sprout consultant, actively campaigned for the approval of flibanserin. The campaign emphasized that several approved treatments for male sexual dysfunction exist, while no such treatment for women was available. [36] The group successfully obtained letters of support from the President of the National Organization for Women, the editor of the Journal of Sexual Medicine, and several members of Congress. Approves Addyi, a Libido Pill for Women".

In case of emergency/overdose

"Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women".

Features and Benefits

Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. The dual control model: The role of sexual inhibition & excitation in sexual arousal and behavior In Janssen, E. (Ed). "Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study". "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant".

CNS Activity

^ "18 June 2010 meeting of the FDA Advisory Committee for Reproductive Health Drugs" (PDF). Archived from the original (PDF) on 13 September 2016. ^ "Drug for sexual desire disorder opposed by panel". Archived from the original on 11 February 2021. ^ a b "Joint Meeting of fildena 200 mg the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee" (PDF). Archived from the original on 26 March 2021. Archived from the original on 18 November 2015. Archived from the original on 6 November 2015.

Addyi (flibanserin) contraindications

Other organizations supporting the approval of flibanserin included the National Council of Women's Organizations, the Black Women's Health Imperative, the Association of Reproductive Health Professionals, National Consumers League, and the American Sexual Health Association. The approval was opposed by the National Women's Health Network, the National Center for Health Research and Our Bodies Ourselves. [42] A representative of PharmedOut said "To approve this drug will set the worst kind of precedent—that companies that spend enough money can force the FDA to approve useless or dangerous drugs. "[43] An editorial in JAMA noted that, "Although flibanserin is not the first product to be supported by a consumer advocacy group in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA's regulation have been particularly noteworthy, as have the extent of advocacy efforts ranging from social media campaigns to letters from members of Congress". In August 2015, Valeant Pharmaceuticals and Sprout Pharmaceuticals announced that Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

Brand Names: US

The initial response since the 2015 introduction of flibanserin to the US market was slow with 227 prescriptions written during the first three weeks. [46] The slow response may be related to a number of factors: physicians require about 10 minutes of online training to get certified; the medication costs about US$400 per month;[47] and questions about the drug's efficacy and need. Archived from the original on 7 June 2022. Archived from the original on 20 October 2020. "Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)".

Approval Year

Archived sexual enhancement pills (PDF) from the original on 14 November 2022. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000:493–538. "Nothing Is Wrong With Your Sex Drive". Archived from the original on 15 July 2017. "Raleigh's Sprout Pharmaceuticals awaits FDA ruling on female libido drug".

What other information should I know?

Archived from the original (PDF) on 5 June 2015. Archived from the original on 15 October 2010. ^ "Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women". Archived from the original on 19 March 2025. Archived from the original on 10 August 2015. Archived from the original on 3 June 2019.

  • Patients should consult healthcare providers for proper assessment before starting flibanserin.
  • Its regulatory approval has sparked ongoing debate about female sexual dysfunction treatments.
  • Flibanserin is not a hormone and does not affect estrogen or testosterone.
  • Pharmacovigilance continues to monitor long-term safety and rare adverse effects.
  • The medication is priced variably, impacting access for some patients.
  • Women are advised not to drink alcohol, as it increases side effect risks.
  • Flibanserin's moderate efficacy underscores the importance of realistic expectations.
  • The goal is to enhance women’s sexual desire and overall satisfaction.
  • Continuous research aims to develop more effective and safer female sexual health drugs.

"'Faux-advocacy,' not science, prompted FDA panel's OK of 'low libido' drug for women, critics charge".

  • Flibanserin, a serotonin receptor modulator, was initially investigated for depression.
  • Its approval marked a historic moment in treating female sexual dysfunction.
  • The medication's side effects necessitate careful patient education.
  • Efficacy is often supported by patient-reported improvements in desire.
  • It does not function as an aphrodisiac but affects brain chemistry.
  • Flibanserin therapy requires adherence to dosing instructions.
  • Women with low libido due to other health issues may not benefit from it.
  • Its role is to complement behavioral or psychological therapy if needed.
  • Research continues into better options for treating female hypoactive sexual desire.

Archived from the original on 30 August 2015. "Evaluation of Flibanserin: Science and Advocacy at the FDA".

 Singes à ventre roux

10+

Années d'expérience

ODDB ONG

Domaines d'interventions

Les objectifs que
nous poursuivons

Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

En savoir plus
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

En savoir plus
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

En savoir plus
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

En savoir plus
ODDB ONG

Nos Projets

ODDB-ONG agit pour l'environnement et le mieux-être des communautés locales.

ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Merci de soutenir nos projets

Votre don nous permet d’agir, merci !

ODDB ONG

Question à nous poser

Une question d'ordre général ?

La biodiversité fait référence à la variété et à la diversité de la vie sur Terre, y compris toutes les espèces d'animaux, de plantes, de micro-organismes et les écosystèmes dans lesquels ils vivent. Cela englobe la richesse génétique au sein des espèces, la diversité des espèces elles-mêmes et la variété des habitats naturels. En résumé, la biodiversité représente la variété de la vie et des écosystèmes qui rendent notre planète unique et fonctionnelle.

Pour poursuivre nos actions pour la planète et en engager de nouvelles, nous sollicitons le soutien de tous. Chaque contribution est importante. Partagez nos campagnes, faites un don, devenez bénévole pour ODDB ONG et aidez-nous à préserver la nature.

Le logo du ODDB ONG est une marque internationale déposée et soumise au droit d'auteur. Toute utilisation ou reproduction est strictement interdite sans autorisation. Si vous souhaitez utiliser le logo dans le cadre d'un partenariat, veuillez écrire à l'adresse suivante. Pour toute autre utilisation, veuillez contacter l'adresse suivante.

Pour toute demande de stage, veuillez consulter régulièrement notre page dédiée au recrutement.

Pour commencer, il est essentiel d'adopter de bonnes habitudes quotidiennes : privilégier une alimentation équilibrée avec moins de protéines animales et favorisant les circuits courts, opter pour des modes de transport durables tels que les transports en commun ou le vélo, améliorer votre efficacité énergétique et votre utilisation numérique, et réduire la production de déchets. Toutes ces pratiques sont détaillées dans la section " Agir au quotidien".

Un accusé de réception vous est envoyé par mail pour vous confirmer la réception de votre dossier de candidature.

Les conséquences de la crise écologique sont manifestes : une agriculture en déclin, des plans d'eau épuisés, un accès difficile à l'eau douce et des forêts en difficulté pour préserver la biodiversité. Notre enjeu environnemental majeur est clair : l'urgence d'agir. Cette nécessité ne concerne plus seulement les générations futures, mais également la population actuelle, qui subit déjà les perturbations profondes engendrées par la crise écologique.
singe a ventre rouge
ODDB ONG

Galerie

Nos Actions En Image

Dendroaspis jamesoni
ODDB ONG
Dendroaspis jamesoni
Benin Potto (Perodicticus potto juju)
ODDB ONG
Benin Potto (Perodicticus potto juju)
Singe tantale (Chlorocebus aethiops tantalus)
ODDB ONG
Singe tantale (Chlorocebus aethiops tantalus)
Female Sitatunga with offspring (Tragelaphus spekii)
ODDB ONG
Female Sitatunga with offspring (Tragelaphus spekii)
Cercopithecus aethiops tantalus
ODDB ONG
Cercopithecus aethiops tantalus
Coucal noir (Centropus senegalensis)
ODDB ONG
Coucal noir (Centropus senegalensis)
Cercopithecus erythrogaster
ODDB ONG
Cercopithecus erythrogaster
Female sitatunga (Tragelaphus spekii)
ODDB ONG
Female sitatunga (Tragelaphus spekii)
Gnanhouizoun community forest, Ouémé valley
ODDB ONG
Gnanhouizoun community forest, Ouémé valley
chouette
ODDB ONG
chouette
Héron cendré (Ardea cinerea)
ODDB ONG
Héron cendré (Ardea cinerea)
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
ODDB ONG
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
ODDB ONG
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
Gnanhouizounmè au couché de soleil
ODDB ONG
Gnanhouizounmè au couché de soleil
Chamaeleo necasi
ODDB ONG
Chamaeleo necasi
Aigrette
ODDB ONG
Aigrette

Nos Statistiques

ODDB en chiffres

10+

10+

Années d'expérience

79

79Ha

de superficies reboisées

14K+

14K+

personnes sensibilisées

320

320

personnes autonomisées

151

151

Stagiaires et bénévoles formés pour suivi de la biodiversité

ODDB ONG

Nos Actualités

Actualités

Nos  Partenaires

Partenaires Techniques

little green guards Chester Zoo Institut des Tortues d'Afrique Conservatoire pour la Protection des Primates National Geographic

Partenaires Financiers

Primate Society of Great Britain SUCO INTERNATIONAL BENIN UP2GREEN The Rufford Foundation IKI